Mira Pharmaceuticals Inc. recently announced progress in its regulatory endeavors, as the acquisition of SKNY Pharmaceuticals is advancing as planned. The company has successfully submitted the necessary regulatory filings for the merger to the U.S. Securities and Exchange Commission $(SEC.UK)$. This acquisition includes SKNY Pharmaceuticals' first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation, SKNY-1. Furthermore, Mira Pharmaceuticals is on track to initiate a Phase 2a trial for Ketamir-2 in neuropathic pain by year-end 2025, pending regulatory clearance. This development marks a significant step in Mira Pharmaceuticals' clinical pipeline expansion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。